Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma/COPD

Peptides

Volumn 28, Issue 9, 2007, Pages 1640-1650

  Onoue, Satomi ^a,b,c   Yamada, Shizuo ^c   Yajima, Takehiko ^a  

^a TOHO UNIVERSITY   (Japan)

^b PFIZER INC   (United States)

^c UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Asthma; COPD; Drug delivery system; Dry powder inhaler; VIP

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIALLERGIC AGENT; BAY 55 9837; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DEXAMETHASONE; GROWTH HORMONE RELEASE FACTOR[8-27]; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR 6; IK 312532; IMMUNOSUPPRESSIVE AGENT; ISOPRENALINE; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; MUSCARINIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE INHIBITOR; RO 25 1392; RO 25 1553; SECRETIN; SECRETIN[16 ARGININE]; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE; VASOACTIVE INTESTINAL POLYPEPTIDE[1-23]; VASOACTIVE INTESTINAL POLYPEPTIDE[1-23][15,20,21 ARGININE 17 LYSINE]; VASOACTIVE INTESTINAL POLYPEPTIDE[1-7][15 LYSINE 16 ARGININE 27 LEUCINE]; VASOACTIVE INTESTINAL POLYPEPTIDE[11,22,28 ALANINE]; VASOACTIVE INTESTINAL POLYPEPTIDE[15,20,21 ARGININE 17 LYSINE]; VASOACTIVE INTESTINAL POLYPEPTIDE[17 VALINE 19 ALANINE 24 GLUTAMINE 27,29 LYSINE 30 ARGININE 31 TYROSINE]; VASOACTIVE INTESTINAL POLYPEPTIDE[9 TYROSINE 18 BETA,BETA DIPHENYLALANINE];

AIRWAY; AMINO ACID SEQUENCE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BIOLOGICAL ACTIVITY; BRONCHODILATATION; CELL PROTECTION; CHEMICAL MODIFICATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG STABILITY; DRY POWDER; HUMAN; IMMUNOMODULATION; IMMUNOREACTIVITY; METERED DOSE INHALER; NEBULIZER; NERVE FIBER; NERVOUS SYSTEM; NEUROMODULATION; NONADRENERGIC NONCHOLINERGIC NERVE; NONHUMAN; PHYSIOLOGY; POWDER INHALER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RESPIRATORY SYSTEM; TISSUE DISTRIBUTION; VASODILATATION;

ANIMALS; ASTHMA; BINDING, COMPETITIVE; DRUG DELIVERY SYSTEMS; HUMANS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; VASOACTIVE INTESTINAL PEPTIDE;

EID: 34548415385     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.04.009     Document Type: Article

References (80)

1. Abad C., Gomariz R.P., and Waschek J.A. Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: focus on VIP and PACAP. Curr Top Med Chem 6 (2006) 151-163
2. Aoshiba K., Tamaoki J., and Nagai A. Acute cigarette smoke exposure induces apoptosis of alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 281 (2001) L1392-L1401
3. Ashok B., Rubinstein I., Tsueshita T., and Onyuksel H. Effects of peptide molecular mass and PEG chain length on the vasoreactivity of VIP and PACAP(1-38) in pegylated phospholipid micelles. Peptides 25 (2004) 1253-1258
4. Basille M., Vaudry D., Coulouarn Y., Jegou S., Lihrmann I., Fournier A., et al. Comparative distribution of pituitary adenylate cyclase-activating polypeptide (PACAP) binding sites and PACAP receptor mRNAs in the rat brain during development. J Comp Neurol 425 (2000) 495-509
5. Bellinger D.L., Lorton D., Brouxhon S., Felten S., and Felten D.L. The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation. Adv Neuroimmunol 6 (1996) 5-27
6. Berger W.E. Paediatric pulmonary drug delivery: considerations in asthma treatment. Expert Opin Drug Deliv 2 (2005) 965-980
7. Bickel U., Yoshikawa T., Landaw E.M., Faull K.F., and Pardridge W.M. Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. Proc Natl Acad Sci USA 90 (1993) 2618-2622
8. Blease K., Lewis A., and Raymon H.K. Emerging treatments for asthma. Expert Opin Emerg Drugs 8 (2003) 71-81
9. Bolin D.R., Michalewsky J., Wasserman M.A., and O'Donnell M. Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma. Biopolymers 37 (1995) 57-66
10. Busse W.W., and Rosenwasser L.J. Mechanisms of asthma. J Allergy Clin Immunol 111 (2003) S799-S804
11. Busto R., Carrero I., Guijarro L.G., Solano R.M., Zapatero J., Noguerales F., et al. Expression, pharmacological, and functional evidence for PACAP/VIP receptors in human lung. Am J Physiol 277 (1999) L42-L48
12. Capasso S., Mazzarella L., Sica F., and Zagari A. Deamination via cyclic imide in asparaginyl peptides. Pept Res 2 (1989) 195-200
13. Caramori G., and Adcock I. Pharmacology of airway inflammation in asthma and COPD. Pulm Pharmacol Ther 16 (2003) 247-277
14. Cardell L.O., Uddman R., and Edvinsson L. Low plasma concentrations of VIP and elevated levels of other neuropeptides during exacerbations of asthma. Eur Respir J 7 (1994) 2169-2173
15. Delgado M., Abad C., Martinez C., Leceta J., and Gomariz R.P. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 7 (2001) 563-568
16. Delgado M., Gomariz R.P., Martinez C., Abad C., and Leceta J. Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock. Eur J Immunol 30 (2000) 3236-3246
17. Delgado M., Munoz-Elias E.J., Gomariz R.P., and Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J Immunol 162 (1999) 1707-1716
18. Delgado M., Munoz-Elias E.J., Gomariz R.P., and Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation. J Immunol 162 (1999) 4685-4696
19. Domschke S., Domschke W., Bloom S.R., Mitznegg P., Mitchell S.J., Lux G., et al. Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects. Gut 19 (1978) 1049-1053
20. Dufes C., Gaillard F., Uchegbu I.F., Schatzlein A.G., Olivier J.C., and Muller J.M. Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain. Int J Pharm 285 (2004) 77-85
21. Dufes C., Olivier J.C., Gaillard F., Gaillard A., Couet W., and Muller J.M. Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. Int J Pharm 255 (2003) 87-97
22. Frode T.S., and Medeiros Y.S. The puzzle of asthma treatment: animal models to genetic studies. Curr Pharm Des 11 (2005) 2515-2524
23. Gozes I., Lilling G., Glazer R., Ticher A., Ashkenazi I.E., Davidson A., et al. Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. J Pharmacol Exp Ther 273 (1995) 161-167
24. Groneberg D.A., Hartmann P., Dinh Q.T., and Fischer A. Expression and distribution of vasoactive intestinal polypeptide receptor VPAC(2) mRNA in human airways. Lab Invest 81 (2001) 749-755
25. Groneberg D.A., Rabe K.F., and Fischer A. Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors. Eur J Pharmacol 533 (2006) 182-194
26. Hashimoto H., Ishihara T., Shigemoto R., Mori K., and Nagata S. Molecular cloning and tissue distribution of a receptor for pituitary adenylate cyclase-activating polypeptide. Neuron 11 (1993) 333-342
27. Hassan M., Refai E., Andersson M., Schnell P.O., and Jacobsson H. In vivo dynamical distribution of 131I-VIP in the rat studied by gamma-camera. Nucl Med Biol 21 (1994) 865-872
28. Hoffmann D., and Wynder L. Chemical constituents and bioactivity of tobacco smoke. In: Zaridge D.G., and Peto R. (Eds). Tobacco, a major international health hazard (1986), World Health Organization, International Agency for Research on Cancer, London
29. Hoshino M., Yanaihara C., Hong Y.M., Kishida S., Katsumaru Y., Vandermeers A., et al. Primary structure of helodermin, a VIP-secretin-like peptide isolated from Gila monster venom. FEBS Lett 178 (1984) 233-239
30. Inagaki N., Kuromi H., and Seino S. PACAP/VIP receptors in pancreatic beta-cells: their roles in insulin secretion. Ann N Y Acad Sci 805 (1996) 44-51
31. Ishihara T., Shigemoto R., Mori K., Takahashi K., and Nagata S. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 8 (1992) 811-819
32. Ito O., and Tachibana S. Vasoactive intestinal polypeptide precursors have highly potent bronchodilatory activity. Peptides 12 (1991) 131-137
33. Ito T., Igarashi H., Pradhan T.K., Hou W., Mantey S.A., Taylor J.E., et al. GI side-effects of a possible therapeutic GRF analogue in monkeys are likely due to VIP receptor agonist activity. Peptides 22 (2001) 1139-1151
34. Jorpes J.E. The isolation and chemistry of secretin and cholecystokinin. Gastroenterology 55 (1968) 157-164
35. Kashimoto K., Nagano Y., Suitani Y., Hamanaka K., Mizumoto T., Tomizaki K., et al. Structure-activity relationship studies of PACAP-27 and VIP analogues. Ann N Y Acad Sci 805 (1996) 505-510
36. Kohler D. Novolizer: the new technology for the management of asthma therapy. Curr Opin Pulm Med 9 Suppl. 1 (2003) S11-S16
37. Luts A., Uddman R., Alm P., Basterra J., and Sundler F. Peptide-containing nerve fibers in human airways: distribution and coexistence pattern. Int Arch Allergy Immunol 101 (1993) 52-60
38. Maruno K., Absood A., and Said S.I. VIP inhibits basal and histamine-stimulated proliferation of human airway smooth muscle cells. Am J Physiol 268 (1995) L1047-L1051
39. Meister A., and Anderson M.E. Glutathione. Annu Rev Biochem 52 (1983) 711-760
40. Miotto D., Boschetto P., Bononi I., Zeni E., Cavallesco G., Fabbri L.M., et al. Vasoactive intestinal peptide receptors in the airways of smokers with chronic bronchitis. Eur Respir J 24 (2004) 958-963
41. Miyata A., Arimura A., Dahl R.R., Minamino N., Uehara A., Jiang L., et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164 (1989) 567-574
42. Mody R., Tramontano A., and Paul S. Spontaneous hydrolysis of vasoactive intestinal peptide in neutral aqueous solution. Int J Pept Protein Res 44 (1994) 441-447
43. Morice A., Unwin R.J., and Sever P.S. Vasoactive intestinal peptide causes bronchodilatation and protects against histamine-induced bronchoconstriction in asthmatic subjects. Lancet 2 (1983) 1225-1227
44. Nathan C. Specificity of a third kind: reactive oxygen and nitrogen intermediates in cell signaling. J Clin Invest 111 (2003) 769-778
45. Newman S.P. Dry powder inhalers for optimal drug delivery. Expert Opin Biol Ther 4 (2004) 23-33
46. Nicole P., Lins L., Rouyer-Fessard C., Drouot C., Fulcrand P., Thomas A., et al. Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide. J Biol Chem 275 (2000) 24003-24012
47. O'Donnell M., Garippa R.J., Rinaldi N., Selig W.M., Tocker J.E., Tannu S.A., et al. Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part II: effect on in vitro and in vivo models of pulmonary anaphylaxis. J Pharmacol Exp Ther 270 (1994) 1289-1294
48. Ohmori Y., Maruyama S., Kimura R., Onoue S., Matsumoto A., Endo K., et al. Pharmacological effects and lung-binding characteristics of a novel VIP analogue, [R15, 20, 21 L17]-VIP-GRR (IK312532). Regul Pept 123 (2004) 201-207
49. Ohmori Y., Onoue S., Endo K., Matsumoto A., Uchida S., and Yamada S. Development of dry powder inhalation system of novel vasoactive intestinal peptide (VIP) analogue for pulmonary administration. Life Sci 79 (2006) 138-143
50. Ohmori Y., Yamada S., Maruyama S., Kimura R., Iwanaga T., Onoue S., et al. Development and pharmacological usefulness of dry powder inhaler of a novel vasoactive intestinal peptide (VIP) analogue. Shizuoka DDS Conference. Shizuoka (2003) 1-11
51. Onoue S., Endo K., Ohmori Y., Yamada S., Kimura R., Yajima T., et al. Long-acting analogue of vasoactive intestinal peptide, [R15, 20, 21, L17]-VIP-GRR (IK312532), protects rat alveolar L2 cells from the cytotoxicity of cigarette smoke. Regul Pept 123 (2004) 193-199
52. Onoue S., Matsumoto A., Nagano Y., Ohshima K., Ohmori Y., Yamada S., et al. Alpha-helical structure in the C-terminus of vasoactive intestinal peptide: functional and structural consequences. Eur J Pharmacol 485 (2004) 307-316
53. Onoue S., Ohmori Y., Endo K., Yamada S., Kimura R., and Yajima T. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide attenuate the cigarette smoke extract-induced apoptotic death of rat alveolar L2 cells. Eur J Biochem 271 (2004) 1757-1767
54. Onoue S., Ohmori Y., Matsumoto A., Yamada S., Kimura R., Yajima T., et al. Structure-activity relationship of synthetic truncated analogues of vasoactive intestinal peptide (VIP): an enhancement in the activity by a substitution with arginine. Life Sci 74 (2004) 1465-1477
55. Onoue S., Ohshima K., Endo K., Yajima T., and Kashimoto K. PACAP protects neuronal PC12 cells from the cytotoxicity of human prion protein fragment 106-126. FEBS Lett 522 (2002) 65-70
56. Onoue S., Waki Y., Hamanaka K., Takehiko Y., and Kashimoto K. Vasoactive intestinal peptide regulates catecholamine secretion in rat PC12 cells through the pituitary adenylate cyclase activating polypeptide receptor. Biomed Res 22 (2001) 77-82
57. Paul S., and Said S.I. Characterization of receptors for vasoactive intestinal peptide solubilized from the lung. J Biol Chem 262 (1987) 158-162
58. Rawlings S.R., and Hezareh M. Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP/vasoactive intestinal polypeptide receptors: actions on the anterior pituitary gland. Endocr Rev 17 (1996) 4-29
59. Robberecht P., De Neef P., and Lefebvre R.A. Influence of selective VIP receptor agonists in the rat gastric fundus. Eur J Pharmacol 359 (1998) 77-80
60. Rubinstein I., Dagar S., Sethi V., Krishnadas A., and Onyuksel H. Liposomal VIP potentiates DNA synthesis in cultured oral keratinocytes. Peptides 22 (2001) 671-675
61. Said S.I. Vasoactive intestinal peptide in the lung. Ann N Y Acad Sci 527 (1988) 450-464
62. Said S.I. Vasoactive intestinal polypeptide and asthma. N Engl J Med 320 (1989) 1271-1273 [editorial]
63. Said S.I. Vasoactive intestinal polypeptide (VIP) in asthma. Ann N Y Acad Sci 629 (1991) 305-318
64. Said S.I., and Mutt V. Polypeptide with broad biological activity: isolation from the small intestine. Science 169 (1970) 1217-1218
65. Sergejeva S., Hoshino H., Yoshihara S., Kashimoto K., Lotvall J., and Linden A. A synthetic VIP peptide analogue inhibits neutrophil recruitment in rat airways in vivo. Regul Pept 117 (2004) 149-154
66. Shirai M., Maki A., Takanami M., Ando K., Nakamura K., Yanaihara N., et al. Content and distribution of vasoactive intestinal polypeptide (VIP) in cavernous tissue of human penis. Urology 35 (1990) 360-363
67. Shivers B.D., Gorcs T.J., Gottschall P.E., and Arimura A. Two high affinity binding sites for pituitary adenylate cyclase- activating polypeptide have different tissue distributions. Endocrinology 128 (1991) 3055-3065
68. Stone K., Bermudez E., and Pryor W.A. Aqueous extracts of cigarette tar containing the tar free radical cause DNA nicks in mammalian cells. Environ Health Perspect 102 (1994) 173-178
69. Suzuki H., Noda Y., Paul S., Gao X.P., and Rubinstein I. Encapsulation of vasoactive intestinal peptide into liposomes: effects on vasodilation in vivo. Life Sci 57 (1995) 1451-1457
70. Szema A.M., Hamidi S.A., Lyubsky S., Dickman K.G., Mathew S., Abdel-Razek T., et al. Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP. Am J Physiol Lung Cell Mol Physiol 291 (2006) L880-L886
71. Takubo T., Banks K., and Martin J.G. Epithelium modulates the potency of vasoactive intestinal peptide in the guinea pig. J Appl Physiol 71 (1991) 2146-2151
72. Tam E.K., and Caughey G.H. Degradation of airway neuropeptides by human lung tryptase. Am J Respir Cell Mol Biol 3 (1990) 27-32
73. Tams J.W., Jorgensen R.M., Holm A., and Fahrenkrug J. Creation of a selective antagonist and agonist of the rat VPAC(1) receptor using a combinatorial approach with vasoactive intestinal peptide 6-23 as template. Mol Pharmacol 58 (2000) 1035-1041
74. Tsutsumi M., Claus T.H., Liang Y., Li Y., Yang L., and Zhu J. Dela Cruz F., Peng X., Chen H., Yung S. L., Hamren S., Livingston J. N., Pan C. Q. A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes. Diabetes 51 (2002) 1453-1460
75. Unger R.H., Dobbs R.E., and Orci L. Insulin, glucagon, and somatostatin secretion in the regulation of metabolism. Annu Rev Physiol 40 (1978) 307-343
76. Usdin T.B., Bonner T.I., and Mezey E. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 135 (1994) 2662-2680
77. Vaudry D., Gonzalez B.J., Basille M., Yon L., Fournier A., and Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52 (2000) 269-324
78. Vines G. Alzheimer's disease-from cause to cure?. Trends Biotechnol 11 (1993) 49-55
79. Wink D.A., and Mitchell J.B. Chemical biology of nitric oxide: insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic Biol Med 25 (1998) 434-456
80. Xia M., Sreedharan S.P., Bolin D.R., Gaufo G.O., and Goetzl E.J. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. J Pharmacol Exp Ther 281 (1997) 629-633